中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(12): 2506-2511

Efficacy of combined versus sequential antiviral therapy in HBeAg-negative chronic hepatitis B patients achieving incomplete virological response during initial antiviral therapy

DOI: 10.12449/JCH251211

  • Department of Liver Diseases，The 980th Hospital of PLA Joint Logistics Support Force，Shijiazhuang 050082，China

Research funding:

Medical Science Research Project of Hebei (20240328)

More Information
  • Corresponding author: KANG Fubiao， kangfb@hebmu.edu.cn （ORCID： 0000-0002-9945-8657）
  • Received Date: 2025-05-21
  • Accepted Date: 2025-07-25
  • Published Date: 2025-12-25
    Abstract
  •   Objective  To investigate the efficacy and safety of combined versus sequential antiviral regimens in HBeAg-negative chronic hepatitis B （CHB） patients achieving incomplete virological response during initial antiviral therapy， and to provide evidence for clinical practice.  Methods  A total of 117 HBeAg-negative CHB patients who attended The 980th Hospital of PLA Joint Logistics Support Force from January 2020 to December 2023 and met the criteria for incomplete virological response were enrolled， and according to the clinical treatment regimen， they were divided into combination group （the original antiviral agent combined with another type of drug） and sequential group （switching to a new drug）. The primary outcome measure was HBV DNA clearance rate at weeks 4， 12， 24， and 48 of combined or sequential therapy， and the secondary outcome measures were alanine aminotransferase （ALT） normalization rate， renal function， myocardial enzymes， and blood lipid profiles. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the chi-square test and the Fisher’s exact test were used for comparison of categorical data between two groups.  Results  Among the 117 CHB patients， there were 49 patients in the combination group and 68 patients in the sequential group. At weeks 24 and 48 of combined or sequential therapy， the combination group had a significantly higher HBV DNA clearance rate than the sequential group （week 24： 95.92% vs 80.88%， χ2=5.761， P=0.016； week 48： 97.96% vs 86.76%， χ2=4.566， P=0.044）. Compared with the sequential group， the combination group showed a significantly higher level of viral inhibition in patients with a high viral load （HBV DNA ≥104 IU/mL） （week 12： 73.33% vs 19.05%， χ2=10.609， P=0.002； week 24： 86.67% vs 47.62%， χ2=5.783， P=0.033）. There was no significant difference in treatment outcome between the two groups among the patients with a low viral load （P>0.05）. The combination group had an ALT normalization rate of 65.31%， 89.80%， 81.63%， and 95.92%， respectively， at 4， 12， 24， and 48 weeks， while the sequential group had an ALT normalization rate of 54.41%， 89.71%， 86.76%， and 94.12%， respectively； there were no significant differences between the two groups （all P>0.05）. There were no abnormalities in renal function， myocardial enzymes， and blood lipids in either group within 48 weeks of combined or sequential therapy.  Conclusion  In HBeAg-negative CHB patients with incomplete virological response， combination therapy has significantly better efficacy than sequential therapy in the high viral load subgroup and can achieve virological suppression more rapidly， and the two regimens have similar efficacy in patients with a low viral load. Both combined and sequential therapies have a favorable safety profile.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    van BÖMMEL F, STEIN K, HEYNE R, et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B[J]. J Hepatol, 2023, 78( 5): 926- 936. DOI: 10.1016/j.jhep.2022.12.018.
    [2]
    MUTIMER D, ELSHARKAWY A, HATHORN E, et al. Rate and determinants of antiviral treatment initiation for patients with HBeAg-negative chronic hepatitis B[J]. J Viral Hepat, 2023, 30( 8): 694- 699. DOI: 10.1111/jvh.13841.
    [3]
    ZHAO XY, LI M, WANG H, et al. Impact of national centralized drug procurement policy on antiviral utilization and expenditure for hepatitis B in China[J]. J Clin Transl Hepatol, 2022, 10( 3): 420- 428. DOI: 10.14218/JCTH.2022.00167.
    [4]
    ZHANG Y, YANG S. Interpretation of 2024 World Health Organization guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2024, 18( 3): 129- 134. DOI: 10.3877/cma.j.issn.1674-1358.2024.03.001.

    张雨, 杨松. 世界卫生组织《慢性乙型肝炎预防、诊断、关怀及治疗指南(2024年版)》解读[J/CD]. 中华实验和临床感染病杂志(电子版), 2024, 18( 3): 129- 134. DOI: 10.3877/cma.j.issn.1674-1358.2024.03.001.
    [5]
    JIN MH, JIANG SW, HU AR, et al. Research progress on differential improvement and mechanism of nucleoside analogues or nucleotide analogues in HBV-related hepato-cellular carcinoma[J]. Chin J Clin Pharmacol Ther, 2025, 30( 6): 835- 848. DOI: 10.12092/j.issn.1009-2501.2025.06.014.

    金梦涵, 蒋素文, 胡爱荣, 等. 核苷与核苷酸类抗病毒药物对乙型肝炎相关肝细胞癌的差异性改善及其机制[J]. 中国临床药理学与治疗学, 2025, 30( 6): 835- 848. DOI: 10.12092/j.issn.1009-2501.2025.06.014.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [7]
    LU FM, FENG B, ZHENG SJ, et al. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. J Clin Hepatol, 2021, 37( 6): 1268- 1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.

    鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37( 6): 1268- 1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.
    [8]
    HE MW, CUI L, CHEN DD, et al. Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: A real-world 48-week extension study[J]. Antimicrob Agents Chemother, 2025, 69( 3): e01827-24. DOI: 10.1128/aac.01827-24.
    [9]
    LI ZB, CHEN DD, JIA YF, et al. Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment[J]. Front Cell Infect Microbiol, 2024, 14: 1413589. DOI: 10.3389/fcimb.2024.1413589.
    [10]
    WONG GL, LEMOINE M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines[J]. J Hepatol, 2025, 82( 5): 918- 925. DOI: 10.1016/j.jhep.2024.12.004.
    [11]
    LUMLEY SF, MOKAYA J, MAPONGA TG, et al. Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field[J]. Lancet Microbe, 2025, 6( 8): 101076. DOI: 10.1016/j.lanmic.2025.101076.
    [12]
    CHOI J, CHOI WM, LIM YS. Are the new nucleos(t)ide analogs better than the old nucleos(t)ide analogs?[J]. Clin Liver Dis, 2023, 27( 4): 809- 818. DOI: 10.1016/j.cld.2023.05.005.
    [13]
    HUANG SC, KAO JH. Combining therapeutic agents to target the immune systems of hepatitis B patients: What do we need to consider?[J]. Expert Rev Gastroenterol Hepatol, 2025, 19( 4): 371- 375. DOI: 10.1080/17474124.2025.2477256.
    [14]
    EMERY JS, FELD JJ. Treatment of hepatitis B virus with combination therapy now and in the future[J]. Best Pract Res Clin Gastroenterol, 2017, 31( 3): 347- 355. DOI: 10.1016/j.bpg.2017.04.007.
    [15]
    ALI SH, SHAH MH, ROY S, et al. Efficacy and safety of tenofovir plus entecavir combination therapy versus tenofovir monotherapy in chronic hepatitis B virus patients with resistance or partial response to entecavir: A systematic review and meta-analysis[J]. J Clin Exp Hepatol, 2025, 15( 4): 102541. DOI: 10.1016/j.jceh.2025.102541.
    [16]
    WANG YH, LIAO J, ZHANG DM, et al. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir[J]. J Med Virol, 2020, 92( 3): 302- 308. DOI: 10.1002/jmv.25608.
    [17]
    WOO HY, PARK JY, BAE SH, et al. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response[J]. Clin Mol Hepatol, 2020, 26( 3): 352- 363. DOI: 10.3350/cmh.2019.0044n.
    [18]
    LIU LP. Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia[D]. Nanchang: Medical School of Nanchang University, 2024.

    刘丽萍. 恩替卡韦经治后低病毒血症的慢性乙型肝炎患者序贯联合富马酸丙酚替诺福韦治疗的疗效及影响因素分析[D]. 南昌: 南昌大学医学部, 2024.
    [19]
    BAZINET M, ANDERSON M, PÂNTEA V, et al. Analysis of HBsAg immuno complexes and cccDNA activity during and persisting after NAP-based therapy[J]. Hepatol Commun, 2021, 5( 11): 1873- 1887. DOI: 10.1002/hep4.1767.
    [20]
    LIU T, WANG H, ZHAO Y, et al. Drug development for chronic hepatitis B functional cure: Recent progress[J]. World J Hepatol, 2025, 17( 4): 105797. DOI: 10.4254/wjh.v17.i4.105797.
    [21]
    LI S, SHI LC, HUANG C, et al. Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis[J]. Ann Hepatol, 2025, 30( 2): 101921. DOI: 10.1016/j.aohep.2025.101921.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (57) PDF downloads(18) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return